ISSN: 2582-7219





# International Journal of Multidisciplinary Research in Science, Engineering and Technology

*(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)*






**Impact Factor: 8.206** **Volume 9, Issue 3, March 2026**

© 2026 IJMRSET | Volume 9, Issue 3, March 2026| DOI: 10.15680/IJMRSET.2026.0903218

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

# A Systemic Herbal Approach for the Prevention and Management of Vitiligo.

**Verma Aditya, Mr. Khare Nripen Prakash, Dr. Shrivastava Satyaendra**

Parijat College of Pharmacy, Indore, India

**ABSTRACT:** Vitiligo is a long-term skin condition in which the body loses its natural pigment, leading to the appearance of white patches. Although it is not harmful or contagious, it can affect a person's confidence and quality of life. This review explains the causes, development, and diagnosis of vitiligo in a simple and comprehensive way. It also discusses available treatments, including medicines, light therapy, and newer options like JAK inhibitors. Special focus is given to herbal remedies such as Bakuchi, Neem, Manjistha, and Turmeric, which may help support treatment naturally. Overall, a combined approach can help manage the condition more effectively.

**KEYWORDS:** Vitiligo, Melonocyte loss, Skin disorder, Auto-immune disease, Herbal treatment, Anti-oxidant therapy.

## I. INTRODUCTION

Vitiligo is a chronic autoimmune skin condition where the body's immune system destroys melanocytes, the cells responsible for producing skin and hair pigment (melanin), leading to the formation of white patches on the skin. It is not life-threatening or contagious but can significantly impact a person's physical appearance and well-being, affecting any part of the body, including hair and mucous membranes. The exact cause is unknown but is believed to involve a combination of genetic, autoimmune, and environmental factors.

The global prevalence of vitiligo is estimated to be 0.5% to 2% of the population, with a slightly higher incidence in some regions such as India, Egypt, and parts of Africa.

**How vitiligo develops**

Vitiligo develops when the immune system mistakenly destroys or inactivates melanocytes, the cells that produce melanin, the pigment that gives skin its colour. This autoimmune reaction leads to white or pale patches on the skin, which can appear on any part of the body

**Loss of melanocytes**

Vitiligo develops when the skin's melanocytes, the cells responsible for producing melanin (skin pigment), are destroyed or become inactive, leading to white patches on the skin. While the exact cause isn't fully understood, it's believed to be a combination of autoimmune factors, where the immune system mistakenly attacks melanocytes, and genetic predisposition

**Decreased / Absent Melanin**

Melanin is the natural pigment produced by melanocytes in the skin, hair, and eyes. It protects the skin from ultraviolet (UV) radiation, determines skin and hair color, and plays a role in immunity and oxidative stress regulation.

**Appearance of White Patches**

White patches on the skin (also called hypo pigmented or depigmented patches) are areas where the skin loses its normal colour due to decreased melanin or absence of melanocytes. These patches may vary in size, shape, and distribution, and can occur anywhere on the body.

## II. TYPES OF VITILIGO

**Non-Segmental Vitiligo (NSV)** :- Acute coronary syndrome (ACS) can be divided into subgroups of ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

angina. ACS carries significant morbidity and mortality and the prompt diagnosis, and appropriate treatment is essential. STEMI diagnosis and management are discussed elsewhere. NSTEMI and Unstable angina are very similar, with NSTEMI having positive cardiac biomarkers. The presentation, diagnosis, and management of NSTEMI are discussed below.

**Segmental Vitiligo (SV) :-** Vitiligo is an acquired pigmentary disorder of the skin presenting as depigmented or hypopigmented macules. It affects 0.1-2% population worldwide, and its prevalence in India is about 0.5-2.5%. Vitiligo can be classified into segmental and non-segmental vitiligo.

**Mixed Vitiligo :-** Mixed vitiligo refers to the coexistence of more than one type of vitiligo pattern in the same individual. Typically, it is a combination of segmental vitiligo (localized, one-sided patches) and non-segmental/generalized vitiligo (symmetrical, widespread patches).

**Sign and Symptoms**

- **Milky-white patches:** These are the most obvious sign, appearing on any part of the body, but often on sun-exposed areas like the face, neck, and hands.
- **Patchy loss of colour**: The patches are typically well-defined and can range from small spots to larger areas where patches merge together.
- **Loss of colour in mucous membranes**: This can affect the inside of the mouth, nose, and genitals.
- **Eye colour changes:** Although rare, vitiligo can affect the color of the iris.

**Etiology**

Vitiligo is a chronic acquired pigmentary disorder characterized by loss of functional melanocytes in the epidermis, leading to well-defined depigmented patches on the skin, hair, and mucous membranes. The exact cause of vitiligo remains multifactorial and not fully understood, involving a complex interplay between genetic, autoimmune, oxidative stress, neural, and environmental factors.

**Genetic Factors :-** Around 20–30% of vitiligo patients have a positive family history.

**Autoimmune Hypothesis :-** The most widely accepted theory suggests that vitiligo is an autoimmune disease.

**Oxidative Stress Hypothesis :-** Oxidative stress plays a crucial role in the initiation of melanocyte destruction.

**Neural Hypothesis :-** The neural hypothesis suggests that neurochemical mediators released from nerve endings in the skin may be toxic to melanocytes.

**Self-Destruction Hypothesis :-** According to this theory, melanocytes self-destruct due to defective melanin synthesis or accumulation of toxic intermediates (like DOPA or quinine's) during melanin production.

**Environmental Factors :-** Environmental triggers often initiate or worsen vitiligo in genetically predisposed individuals.

**Common triggers include**

- Physical trauma or friction (Koebner phenomenon)
- Sunburn
- Chemical exposure (phenols, catechol)
- Emotional stress

**Pathophysiology**

Vitiligo is a chronic depigmenting skin disorder caused by the loss or dysfunction of melanocytes, the pigment-producing cells in the epidermis. The exact pathophysiology is multifactorial and complex, involving genetic predisposition, immune dysregulation, oxidative stress, and environmental triggers, all contributing to melanocyte destruction.

**Normal Melanocyte Function**

**Key Mechanisms in the Pathophysiology of Vitiligo**

A. Genetic Predisposition

B. Autoimmune Mechanisms

C. Oxidative Stress and Cellular Damage

D. Melanocyte Detachment and Apoptosis (Melanocytorrhagy)

© 2026 IJMRSET | Volume 9, Issue 3, March 2026| DOI: 10.15680/IJMRSET.2026.0903218

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

E. Environmental and Chemical Trigger

**Immunopathogenesis Cascade (Stepwise Mechanism)**

1.Initial Trigger
2.Innate Immune Activation
3.Cytokine Amplification
4.Loss of Melanocyte

**Pathological Findings**

- **Epidermis:** Absence or reduction of melanocytes in affected areas.
- **Dermis:** Mild inflammatory infiltrate of lymphocytes, primarily CD8+ T cells.
- **Biochemical:** Elevated levels of ROS and reduced antioxidant enzymes.
- **Immunological:** Presence of melanocyte-specific antibodies in serum.

## III. DIAGNOSIS

Vitiligo is primarily diagnosed clinically, based on the appearance of well-defined depigmented (white) macules or patches on the skin. However, additional investigations may be done to confirm the diagnosis, rule out other causes of hypopigmentation, and identify associated autoimmune conditions.

**Clinical Diagnosis**

A. History Taking
B. Physical Examination

**Diagnostic Tools and Tests**

A. Wood's Lamp Examination
B. Dermoscopy

| Test: | Purpose: |
|---|---|
| Thyroid function tests (T3, T4, TSH) | To detect autoimmune thyroiditis (common comorbidity) |
| Anti-thyroid antibodies | Autoimmune screening |
| Fasting blood sugar / HbA1c | To rule out diabetes mellitus |
| ANA (Antinuclear Antibody) test | Screening for autoimmune connective tissue disorders |
| Vitamin B12 and folate levels | For nutritional assessment (sometimes low in vitiligo) |

**Laboratory Investigations**

**Differential Diagnosis**

**TREATMENT**

Vitiligo is a chronic pigmentary disorder characterized by the loss of functional melanocytes, leading to depigmented white patches on the skin. While there is no definitive cure, various treatments aim to restore skin color (repigmentation), stabilize the disease, and improve cosmetic appearance and psychological well-being.

**Goals of Treatment**

- Halt progression of depigmentation.
- Achieve repigmentation of white patches.
- Maintain long-term remission.
- Enhance the patient's quality of life.

© 2026 IJMRSET | Volume 9, Issue 3, March 2026| DOI: 10.15680/IJMRSET.2026.0903218

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

**General Treatment Approaches**
**A. Medical (Pharmacological) Therapy**
1.Topical Corticosteroids
2.Topical Calcineurin Inhibitors
3.Topical Vitamin D Analogues
**B. Phototherapy (Light-Based Therapy)**
1.Narrowband Ultraviolet B (NB-UVB)
2.PUVA Therapy (Psoralen + UVA)
**C. Surgical Treatments**
1.Skin Grafting Techniques
2.Cellular Grafting
**D. Depigmentation Therapy**
**E. Adjunctive Therapies**
1.Antioxidants & Nutritional Support.
2.Herbal and Ayurvedic Remedies

## IV. MANAGEMENT

The management of vitiligo focuses on stopping or slowing the progression of depigmentation, inducing repigmentation, and improving the cosmetic appearance and psychological well-being of affected individuals.

**General Management**
A. Patient Education and Counselling
B. Lifestyle Modifications

**Surgical Management**
**A. Techniques**
1.Split-Thickness Skin Grafting
2.Cellular Grafting (Melanocyte Transplantation)
**Cosmetic Camouflage**
**Depigmentation Therapy**
For patients with extensive vitiligo (>50% body surface area) who prefer uniform color
**Psychological and Social Support**
**Emerging and Experimental Therapies**

**HERBAL TREATMENT**
Herbal and natural remedies aim to stimulate melanogenesis, modulate immune responses, and protect melanocytes from oxidative stress.

**Bakuchi**
**Biological Name:** Psoralea corylifolia
**Family:** Fabaceae (Leguminosae)
**Common Name:** Babchi
**Part Used:** Seeds
**Key Constituents:** Psoralen, Bakuchiol
**Use:** Melanin production badhata hai (vitiligo me main drug)

**Neem**
**Biological Name:** Azadirachta indica
**Family:** Meliaceae
**Common Name:** Neem
**Part Used:** Leaves / Bark
**Key Constituents:** Azadirachtin, Nimbin
**Use:** Antibacterial, antifungal, blood purifier

© 2026 IJMRSET | Volume 9, Issue 3, March 2026| DOI: 10.15680/IJMRSET.2026.0903218

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

**Manjistha**
**Biological Name:** Rubia cordifolia
**Family:** Rubiaceae
**Common Name:** Indian Madder
**Part Used:** Roots
**Key Constituents:** Alizarin, Purpurin
**Use:** Blood purifier, skin disorders me helpful

**Turmeric**
**Biological Name:** Curcuma longa
**Family:** Zingiberaceae
**Common Name:** Haldi
**Part Used:** Rhizome
**Key Constituents:** Curcumin
**Use:** Anti-inflammatory, antioxidant

**PREVENTION**

While there is no guaranteed way to completely prevent vitiligo (since genetic and autoimmune factors play a major role), certain preventive strategies can help reduce the risk, slow disease progression, and limit recurrence after treatment.

1. Avoidance of Skin Trauma (Koebner Phenomenon Prevention)
2. Protection from Sun Exposure
3. Reduce Oxidative Stress
4. Manage Emotional and Physical Stress
5. Maintain a Healthy Immune System
6. Avoid Chemical Exposure
7. Early Detection and Intervention
8. Family and Genetic Counseling
9. Herbal and Natural Supportive Care

## V. LITERATURE REVIEW

**Taieb A., et al. (2023)** — Updated global review concluded that integrated approaches encompassing topical, systemic, surgical, and psychological therapies provide the best long-term regimentation and improvement in quality of life. The authors emphasized personalized treatment protocols based on disease stability and extent. They also highlighted the importance of patient education and adherence for sustained results. The review urged multidisciplinary collaboration to manage both clinical and psychosocial aspects effectively.

**Rosmarin D., et al. (2023)** — Two-year follow-up of ruxolitinib cream users demonstrated durable and progressive repigmentation with minimal relapse, confirming its role as a long-term therapeutic option. The study established that maintenance therapy supports melanocyte survival post-repigmentation. Adverse effects were mild, suggesting good tolerability. It validated JAK inhibition as a cornerstone mechanism in vitiligo control.

**Ezzedine K., et al. (2022)** — A global consensus outlined future research priorities, stressing the development of biomarkers for disease activity, new molecular targets, and patient-centered clinical outcomes. The panel underscored the need for harmonized diagnostic criteria and standardized outcome measures in trials. It emphasized inclusion of diverse ethnic populations in research. The consensus aimed to accelerate translational progress from bench to bedside.

**Hamzavi I., et al. (2022)** — A Phase 3 randomized controlled trial established topical ruxolitinib cream's efficacy in achieving significant facial and total-body repigmentation versus vehicle. The findings confirmed JAK inhibition as a validated mechanism in vitiligo pathophysiology. Safety outcomes were favorable, supporting long-term use. The study set a benchmark for future topical immunomodulators.

**Zeng Q., et al. (2021)** — Preclinical data revealed that ginkgo biloba extract reduced oxidative stress, enhanced melanocyte viability, and protected against apoptosis. The study proposed its use as an adjunct in vitiligo management

ISSN: 2582-7219 | www.ijmrset.com | Impact Factor: 8.206| ESTD Year: 2018|

International Journal of Multidisciplinary Research in Science, Engineering and Technology (IJMRSET)

(A Monthly, Peer Reviewed, Refereed, Scholarly Indexed, Open Access Journal)

due to its antioxidative and anti-inflammatory mechanisms. It suggested synergistic potential with phototherapy. These findings support integrating phytotherapy into conventional regimens.

**Bergqvist C., et al. (2021)** — This review of diagnostic modalities highlighted Wood's lamp, dermoscopy, and histopathology as essential tools for accurate vitiligo assessment. It emphasized differentiating vitiligo from other hypopigmentary disorders like pityriasis alba and post-inflammatory hypopigmentation. The authors advocated for standardized diagnostic algorithms. Early and precise diagnosis was noted as critical for effective intervention.

**Liu L.Y., et al. (2021)** — A systematic review of oral JAK inhibitors such as tofacitinib and baricitinib showed promising outcomes in resistant vitiligo cases. Combination with phototherapy produced synergistic repigmentation effects. The analysis noted immunomodulatory correction of IFN-γ signaling as a key mechanism. Authors called for large-scale controlled trials to establish long-term efficacy and safety.

## VI. SUMMARY & CONCLUSION

Vitiligo is a chronic autoimmune depigmenting disorder characterized by the loss or functional impairment of melanocytes, leading to well-defined white patches on the skin. It affects about 0.5–2% of the global population and has both physical and psychological impacts. The condition arises from a multifactorial interplay of genetic susceptibility, autoimmune reactions, oxidative stress, neural factors, and environmental triggers. Diagnosis is mainly clinical, aided by Wood's lamp examination, dermoscopy, and histopathology, while laboratory tests help identify associated autoimmune diseases. Conventional treatment aims to stop disease progression and induce repigmentation using topical corticosteroids, calcineurin inhibitors, vitamin D analogues, systemic corticosteroids, phototherapy (NB-UVB, PUVA), and surgical techniques such as autologous melanocyte-keratinocyte transplantation. Recent innovations, including JAK inhibitors like ruxolitinib and tofacitinib, have demonstrated promising outcomes in repigmentation and disease stabilization.

## REFERENCES

1. Taïeb A., Picardo M. Vitiligo: A Comprehensive Guide to Pathogenesis and Treatment. Springer, 2019; pp. 45–62.
2. Ezzedine K., Lim H.W., Suzuki T. Global Consensus on Vitiligo Diagnosis and Management. JAMA Dermatology, 2020; 156(1): 13–24.
3. Schallreuter K.U., Rokos H. Oxidative Stress in Vitiligo: Biochemical Mechanisms and Clinical Correlations. Free Radic Biol Med, 2018; 124: 620–635.
4. Jin Y., et al. Genetic Associations of HLA and TYR Loci with Vitiligo Susceptibility. Nature Genetics, 2016; 48(1): 20–29.
5. Speeckaert R., Lambert J. Vitiligo: An Autoimmune and Stress-Related Skin Disorder. Autoimmun Rev, 2017; 16(9): 937–945.
6. Bergqvist C., Ezzedine K. Vitiligo Diagnosis and Differential Evaluation. Dermatol Clin, 2021; 39(2): 181–195.
7. Dell'Anna M.L., Picardo M. Oxidative Stress Markers in Vitiligo. J Invest Dermatol, 2019; 139(1): 42–49.
8. Gauthier Y., Benzekri L. Surgical Treatments for Stable Vitiligo. Clin Dermatol, 2018; 36(6): 688–696.
9. Passeron T., et al. Efficacy of NB-UVB in Vitiligo Management: A Meta-Analysis. Br J Dermatol, 2019; 181(6): 1253–1261.
10. Radakovic-Fijan S., et al. Topical Tacrolimus in Facial Vitiligo: A Controlled Study. Arch Dermatol, 2017; 153(2): 180–185.
11. Abdel-Malek Z.A., et al. Melanocyte Biology in Vitiligo. Pigment Cell Melanoma Res, 2020; 33(1): 17–29.
12. Lotti T., et al. Systemic Corticosteroid Pulse Therapy for Vitiligo. Dermatol Ther, 2018; 31(3): 298–306.
13. Hamzavi I., et al. Efficacy of Ruxolitinib Cream in Vitiligo: Phase 3 Study. N Engl J Med, 2022; 387: 1101–1112.
14. Rosmarin D., et al. Long-Term Efficacy of Topical Ruxolitinib in Vitiligo. J Am Acad Dermatol, 2023; 88(2): 255–266.
15. Liu L.Y., et al. Oral JAK Inhibitors in Refractory Vitiligo: A Systematic Review. Dermatol Ther, 2021; 34(7): 325–339.

INTERNATIONAL STANDARD SERIAL NUMBER INDIA

# INTERNATIONAL JOURNAL OF MULTIDISCIPLINARY RESEARCH

## IN SCIENCE, ENGINEERING AND TECHNOLOGY

| Mobile No: +91-6381907438 | Whatsapp: +91-6381907438 | ijmrset@gmail.com |

www.ijmrset.com